FDA Grants Extra Patent Time for Skinvive Beauty Booster
Published Date: 5/14/2025
Notice
Summary
The FDA has officially set the review period for SKINVIVE, a medical device, so its patent can be extended. This means the company behind SKINVIVE gets more time to protect their invention, helping them keep their competitive edge. If you’re in the medical or patent world, watch for this update—it affects patent timing and could impact market exclusivity.
No Economic Impacts Identified for this Document
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19563, Improving Patient Access to Deceased Donor Islet Cells and Cell Products; Request for Information
The government wants your ideas on how to make it easier and safer for people with Type 1 diabetes to get special cells from deceased donors that help manage their disease. They’re thinking about new rules to treat these cells like organs, which could improve how they’re shared and used. If you have thoughts, send them by November 9, 2026—this could change how patients get life-changing treatments and how doctors handle them.
2026-19419, Sanjay Kumar: Final Debarment Order
Sanjay Kumar is banned for 5 years from importing any drugs into the U.S. because he was convicted of a serious crime involving fake goods. He didn’t respond to the FDA’s notice, so the ban starts on September 23, 2026. He can apply to end the ban anytime, but must follow special rules to keep info private.
Previous / Next Documents
Previous: 2025-08448, Proposed Collection; Comment Request; Extension: Rule 18a-3
The SEC wants to keep Rule 18a-3 going, which helps nonbank security-based swap dealers keep an eye on risky trades and follow safety rules. About 13 dealers spend around 60 hours a year making sure everything’s in check, so the paperwork and time stay about the same. No big changes or costs, just a smooth extension to keep the financial playground safe and sound.
Next: 2025-08450, Determination of Regulatory Review Period for Purposes of Patent Extension; EPKINLY
The FDA has officially set the review period for EPKINLY, a new medicine, so its patent can be extended. This helps the company behind EPKINLY get extra time to protect their invention and encourages more innovation. If you’re involved in drug development or patents, this update affects when and how long patent protections last, potentially impacting money and market timing.